The medicines differ in administration instructions, adverse effects, and expected benefits
This is a standard rule across compounded prescription medications, not a policy specific to altRx
While semaglutide demonstrated a favorable safety and tolerability profile and was associated with modest changes in AD-related biomarkers, including plasma high-sensitivity C-reactive protein and AD-relevant cerebrospinal fluid biomarkers, it did not demonstrate superiority over placebo on the primary clinical endpoint, change in the clinical dementia ratingsum of boxes (CDR-SB) score at week 104 68
Both medications produce weight loss even without significant dietary changes due to their powerful appetite suppression effects
AND ITS SERVICE PROVIDERS ASSUME NO LIABILITY FOR INACCURACIES OR MISSTATEMENTS REGARDING ANY PRODUCT.
In 2026, online platforms are becoming stricter across the board especially for products that fall into regulated or sensitive categories